Clinical Features and Prognostic Impact of Splicing Factor Mutations and Their Co-Mutations in Acute Myeloid Leukemia.
The clinical and prognostic significance of splicing factor (SF) mutations in newly diagnosed adult de novo acute myeloid leukemia (AML) remains incompletely defined. The SFmut group had a lower composite complete remission rate (50.9% vs 71.3%, p = 0.003) and significantly shorter overall survival (median 6.73 vs 19.07 months, p < 0.001).
The clinical and prognostic significance of splicing factor (SF) mutations in newly diagnosed adult de novo acute myeloid leukemia (AML) remains incompletely defined. The SFmut group had a lower composite complete remission rate (50.9% vs 71.3%, p = 0.003) and significantly shorter overall survival (median 6.73 vs 19.07 months, p < 0.001).
What the study was
- Study design
- Journal Article
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Acta haematologica
Why it surfaced
Score 6/10: Journal Article, human study, Exploratory. 🟢 NEAR_TERM_IMPLEMENTABLE — Near-term implementable finding
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.